Raymond Prudo-Chlebosz - 02 Dec 2024 Form 4 Insider Report for Akari Therapeutics Plc (AKTX)

Role
Director
Signature
/s/ Wendy F. DiCicco, as Attorney-in-Fact
Issuer symbol
AKTX
Transactions as of
02 Dec 2024
Net transactions value
+$1,006,286
Form type
4
Filing time
03 Dec 2024, 17:48:04 UTC
Previous filing
02 Jul 2024
Next filing
10 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKTX Ordinary Shares, par value $0.0001 per share Award $503,143 +419,286,000 +11% $0.001200 4,077,124,600 02 Dec 2024 Direct F1, F2
holding AKTX Ordinary Shares, par value $0.0001 per share 38,709,600 02 Dec 2024 Praxis Trustees Limited F1
holding AKTX Ordinary Shares, par value $0.0001 per share 800,766,600 02 Dec 2024 RPC Pharma Limited F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKTX Warrants (Right to Buy) Award $503,143 +419,286,000 $0.001200 419,286,000 02 Dec 2024 Ordinary Shares, par value $0.0001 per share 419,286,000 $0.001100 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares.
F2 On December 2, 2024, the Reporting Person acquired 419,286,000 Ordinary Shares and accompanying warrants to purchase up to 419,286,000 Ordinary Shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of November 13, 2024. The combined purchase price was $0.001193 per Ordinary Share and accompanying warrant.
F3 The warrants have an exercise price of $0.001130 per Ordinary Share.